Danaher Corporation reported strong Q4 2023 earnings, with adjusted EPS at $2.09, beating expectations of $1.91, and revenue at $6.41B, surpassing the expected $6.02B. HCA Healthcare also had a remarkable quarter, with its stock jumping 4.6% pre-market, reporting solid fourth-quarter results and providing upbeat 2024 guidance. Boston Scientific's Q4 earnings beat estimates, with adjusted EPS at $0.55, higher than the estimated $0.51, and revenue at $3.73B, exceeding the estimated $3.59B. Phillips 66 also outperformed, reporting an adjusted EPS of $3.09, surpassing the estimated $2.34, and sales of $38.74B, higher than the estimated $36.50B. Mastercard's Q4 results showed strong adjusted EPS at $3.18, slightly above the estimated $3.08, and net revenue at $6.55B, just above the estimated $6.5B. HCA Healthcare's profits in the fourth quarter reached $1.6 billion, with revenues totaling $17.3 billion, approaching an all-time high for the company.
HCA Healthcare’s stock price is approaching an all-time high: the company earned $1.6 billion in profits during the fourth quarter, bringing in $17.3 billion in revenues, @MitchABlack reports: https://t.co/A5S5gOXWCi
$PSX (+2.4% pre) Phillips 66 Delivers Strong 4Q 2023 Results, Advances Strategic Priorities https://t.co/TIHFQR5kcu
$BSX (+4.2% pre) Boston Scientific Corp (BSX) Posts Strong Q4 and Full Year 2023 Results https://t.co/s3nL2o9y80
$MA RESULTS: Q4 ❖ ADJ EPS $3.18, EST $3.08 ❖ EPS $2.97 ❖ Net revenue $6.55B, EST $6.5B ❖ Operating margin 51.5%, EST 55.9% ❖ Cross-border volumes +18%, EST +18.3% ❖ Purchase volume $1.92 trillion, EST $1.92 trillion ❖ Purchase volume +11%, EST +10.6% ❖ Gross Dollar…
Happening now: Q4 and full year 2023 earnings conference call & webcast. Tune in here: https://t.co/Uo0TgakXza $BSX
Refiner Phillips 66 beats quarterly profit estimates #oott https://t.co/HMcSlgvotD
$PSX | Phillips 66 Q4 Earnings: - Adj. EPS $3.09 (Est. $2.34) - Sales $38.74B (Est. $36.50B)
Boston Scientific’s stock jumps 5.8% after earnings beat and upbeat guidance https://t.co/Opuqssx2Rj
Boston Scientific announces results for Q4 and Full Year 2023: https://t.co/30A2pohNBB $BSX https://t.co/wM1SrIAU2S
$BSX | Boston Scientific Q4 Earnings: - Adjusted EPS $0.55 (Est. $0.51) - Sales $3.73B (Est. $3.59B)
$BSX | Boston Scientific Q4 23 Earnings: - Adj EPS: $0.55 (est $0.51) - Revenue: $3.73B (est $3.59B) - Sees Q1 Adj EPS $0.50-0.52 (est $0.52)
$HCA Q4 beat. While MA insurers say they saw late Q4 spike in admits, the health system reported same facility equivalent admissions +3.9%, with revenue per admission +6.9%. MA admits were +10% in the quarter - but execs say that's consistent with rest of the year. https://t.co/8BtyfX2bUA
$HCA (+4.6% pre) HCA Healthcare Reports Fourth Quarter 2023 Results and Provides 2024 Guidance https://t.co/MCd7jHzyFM
HCA’s stock jumps as fourth-quarter results top expectations https://t.co/1NSBTobQRU
$HCA another beast of a quarter, one of the Elite quality Healthcare names
$DHR | Danaher Q4 23 Earnings: - Adj EPS: $2.09 (exp $1.91) - Revenue: $6.41B (exp $6.02B) - Adj Free Cash Flow $1.20B (exp 1.84B) - Sees FY Non-GAAP Core Revenue Down Low-Single Digits